NATALIYA SEVASTYANOVA: Open Payments
NPI 1518449198 · SPRINGFIELD, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$842 in 38 payments from 8 companies in 2025. Trend: 2023 $539 · 2024 $483 · 2025 $842
Food & beverage: $842
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 12 | $181 |
| AstraZeneca Pharmaceuticals LP | 7 | $165 |
| Grifols USA, LLC | 4 | $116 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $112 |
| GENZYME CORPORATION | 2 | $104 |
| Amgen Inc. | 4 | $83 |
| Regeneron Healthcare Solutions, Inc. | 3 | $60 |
| INOGEN, INC. | 1 | $21 |
Products named: DUPIXENT, Prolastin-C Liquid, FASENRA, TEZSPIRE, NUCALA, TRELEGY ELLIPTA, OFEV, JASCAYD.
Industry payments across MA — which companies pay providers there.
